Knochenmarktransplantation - eine neue Option bei schwerem SLE?

Euler, H.; Fastenrath, Sven; Dreger, Peter; Schmitz, Nicole; Am, Marmont

doi:10.1055/s-2008-1043696

Cited by 1 publication

(1 citation statement)

References 33 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concomitant reconstitution of a renewed and complex T-cell repertoire after HSCT has also been demonstrated indicating de novo lymphopoiesis and acquisition of self-tolerance [117]. In contrast, relapses in the order of 20 to 70% [118], disease persistence after autologous transplantation [119,120] and progression in brain atrophy [121,122], have been reported. Furthermore, whilst less intense immunosuppressive regimens have been adopted in patients receiving autologous grafts, this form of preconditioning may not suffice.…”

Section: Clinical Experience Of Autologous Hsct To Treat Msmentioning

confidence: 95%

Stem Cell and Gene Therapeutic Strategies for the Treatment of Multiple Sclerosis

Siatskas¹,

Bernard

2009

CMM

View full text Add to dashboard Cite

Multiple sclerosis is a disease of the central nervous system that predmoninantly affects young adults. The pathogenic mechanisms are complex, however numerous studies indicate that the disease is initiated by an autoimmune attack on protein targets present in the central nervous system. Given that a dysfunctional immune system perpetuates the pathophysiological mechanisms that characterize this inflammatory disorder, several therapeutic approaches that target immune cells or their secreted mediators have been generated and are currently used clinically. Although these strategies have been partially beneficial to a proportion of patients, current therapies are not particularly effective at preventing disease progression. As such there is a large and unmet need for the development of more effective treatments. Owing to a number of promising results obtained in mouse models of multiple sclerosis, cell therapies implementing hematopoietic, mesenchymal and neural stem cells may provide practical vehicles for in situ immunomodulation, neuroprotection and regeneration. In concert with these approaches, gene therapy strategies are being investigated to restore antigen-specific tolerance or to deliver anti-inflammatory molecules. Furthermore targeted delivery of glial or neurotropic factors, which counteract the activity of inhibitory molecules within the neurodegenerative component of the lesion, is also being pursued. It is conceivable that these experimental approaches alone, or in combination with emerging and current treatments, may establish a rational protocol for the treatment of multiple sclerosis and potentially other autoimmune disorders.

show abstract